GOSS
Gossamer Bio, Inc.
Key Financials
Net Income
$-170370000
↓ 201.4%
Operating Income
$-170728000
↓ 184.9%
Revenue
$48.5M
↓ 57.7%
Total Assets
$172.2M
↓ 45.4%
Total Liabilities
$295.0M
↑ 3.2%
Shareholders' Equity
$-122760000.00
↓ 516.2%
EPS (Diluted)
$-0.75
↓ 200.0%
Cash & Equivalents
$37.7M
↓ 18.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/17/2026 | View on SEC |
| SCHEDULE 13D | 6/11/2026 | View on SEC |
| SCHEDULE 13G | 6/11/2026 | View on SEC |
| SCHEDULE 13G | 6/11/2026 | View on SEC |
| DEF 14A | 6/9/2026 | View on SEC |
| SCHEDULE 13G | 6/9/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GOSS |
| Company Name | Gossamer Bio, Inc. |
| CIK | 1728117 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 684-1300 |